Vins Bioproducts Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Vins Bioproducts Limited Pharmaceutical Export Portfolio Dataset — 3 Products, $15.7M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Vins Bioproducts Limited — Pharmaceutical Exporter Profile (2026) | 3 Products, $15.7M Trade | TransData Nexus

Vins Bioproducts Limited

Indian Pharmaceutical Exporter · Other Specialist · $15.7M Total Trade · DGFT Verified

Vins Bioproducts Limited is an Indian pharmaceutical exporter with a total trade value of $15.7M across 3 products in 1 therapeutic categories. Based on 383 verified export shipments from Indian Customs (DGFT) records, Vins Bioproducts Limited is the #1 Indian exporter in 1 product including Antitoxin. Top exports include Antitoxin ($9.0M), Serum ($6.0M), Immunoglobulin ($700.0K).

Vins Bioproducts Limited — Export Portfolio & Destination Treemap

Vins Bioproducts Limited pharmaceutical export portfolio — 3 products across 1 therapeutic categories. Source: Indian Customs (DGFT).

Who is Vins Bioproducts Limited? — Company Overview & Market Position

Vins Bioproducts Limited, established on February 17, 1997, is a Hyderabad-based biopharmaceutical company specializing in the production of life-saving immunobiologicals. The company is registered under the Corporate Identification Number (CIN) U24110TG1997PLC026437. Its authorized and paid-up capital stands at ₹200 million (approximately $2.7 million USD). The registered office is located at 806, Essjay House, Road No.3, Banjara Hills, Hyderabad, Telangana, India 500034. Vins Bioproducts Limited is a public unlisted company, classified as a non-government company limited by shares. The company employs between 51 to 200 individuals, reflecting its substantial operational scale. For more information, visit their official website at www.vinsbio.in.

What Does Vins Bioproducts Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Antitoxin$9.0M 2Serum$6.0M

Product Portfolio — Top 3 by Export Value

Vins Bioproducts Limited exports 3 pharmaceutical products across 1 therapeutic categories. Market leader (#1 exporter) in 1 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Antitoxin	Other	$9.0M	225	64.7%	1
2	Serum	Other	$6.0M	144	21.1%	2
3	Immunoglobulin	Other	$700.0K	14	0.4%	14

Vins Bioproducts Limited exports 3 pharmaceutical products across 1 therapeutic categories with a total export value of $15.7M. The company is the #1 Indian exporter in 1 product: Antitoxin. The top category is Other (100.0% of portfolio), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Vins Bioproducts Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Vins Bioproducts Limited operates state-of-the-art manufacturing facilities in Telangana, India, approximately 40 kilometers from Hyderabad. These facilities are approved by the Pharmaceutical Inspection Co-operation Scheme (PIC/S), ensuring adherence to international manufacturing standards. The company also maintains a 150-acre farm housing over 2,000 equines, which are integral to their immunoglobulin production process. This combination of advanced manufacturing infrastructure and dedicated animal husbandry underscores Vins Bioproducts' commitment to quality and innovation in the biopharmaceutical sector.

3Key Leadership

The leadership team at Vins Bioproducts Limited is helmed by CEO Khushboo Daga, who has been instrumental in steering the company towards significant milestones. Under her guidance, the company has achieved recognition, including the BW Healthcare 40 Under 40 Award in 2026. The Board of Directors comprises:

Balkishan Badruka
Ajit Nair
Aruna Malani
Sura Surendranath Reddy
Shreedass Narayandas Daga
Shivlal Ramnath Daga
Siddarth Daga
Ravindra Reddy Puli

These leaders bring a wealth of experience and strategic vision to the company's operations.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Vins Bioproducts Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Vins Bioproducts Limited has established a significant presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's products are approved by the World Health Organization (WHO), facilitating access to these markets. Additionally, Vins Bioproducts collaborates with international organizations such as WHO, UNICEF, UNDP, and PAHO, enhancing its global reach and credibility. This strategic positioning underscores the company's commitment to meeting stringent regulatory standards and expanding its footprint in key international markets.

2Emerging Markets

Vins Bioproducts Limited has made significant inroads into emerging markets across Africa, Latin America, and Southeast Asia. The company's WHO prequalification status enables it to supply essential immunobiologicals to these regions, addressing critical healthcare needs. By leveraging its expertise and regulatory approvals, Vins Bioproducts contributes to improving healthcare outcomes in underserved areas, demonstrating its commitment to global health.

3Geographic Strategy

Vins Bioproducts Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Vins Bioproducts Limited's products are approved by the World Health Organization (WHO), facilitating access to regulated markets. However, specific details regarding FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. This information is crucial for assessing the company's standing in the U.S. market and its compliance with FDA regulations.

2WHO & EU GMP

Vins Bioproducts Limited's manufacturing facilities are approved by the Pharmaceutical Inspection Co-operation Scheme (PIC/S), ensuring adherence to international Good Manufacturing Practice (GMP) standards. The company's products are also approved by the World Health Organization (WHO), facilitating access to regulated markets. However, specific details regarding EU GMP certificates and European Directorate for the Quality of Medicines & HealthCare (EDQM) status are not publicly available. This information is essential for evaluating the company's compliance with European regulatory standards.

3CDSCO & Indian Regulatory

Vins Bioproducts Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Vins Bioproducts Limited operates in a competitive landscape with several key players in the biopharmaceutical sector, particularly in the production of immunobiologicals. While specific market share data is not publicly available, the company's focus on life-saving antisera and antitoxins positions it as a significant entity in this niche market. The company's collaborations with international organizations such as WHO, UNICEF, UNDP, and PAHO enhance its competitive edge by expanding its global reach and credibility.

2Key Differentiators

Vins Bioproducts Limited's key differentiators include its specialized focus on life-saving immunobiologicals, advanced manufacturing facilities approved by PIC/S, and a 150-acre equine farm integral to its production process. The company's collaborations with international organizations such as WHO, UNICEF, UNDP, and PAHO further distinguish it in the global market. These factors collectively contribute to the company's competitive advantage in the biopharmaceutical industry.

3Strategic Position

Vins Bioproducts Limited's current strategic direction focuses on the production of life-saving immunobiologicals, including antisera for snake and scorpion bites, antitoxins for tetanus, diphtheria, and gangrene, and rabies immunoglobulins. The company's collaborations with international organizations such as WHO, UNICEF, UNDP, and PAHO indicate a strategic emphasis on global health initiatives. Future outlooks suggest potential expansion into new therapeutic areas and markets, leveraging its manufacturing capabilities and regulatory approvals.

Buyer Due Diligence Brief — Evaluating Vins Bioproducts Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Vins Bioproducts Limited has demonstrated a consistent track record in the production and export of life-saving immunobiologicals, with a total export value of $15.7 million USD across 383 shipments. The company's portfolio is concentrated, with the top five products accounting for 100% of its exports, indicating a focused approach to product development and market penetration. The absence of publicly available records of regulatory actions suggests a reliable and compliant manufacturing process. However, the lack of detailed information regarding FDA facility registrations, EU GMP certificates, and CDSCO approvals limits a comprehensive assessment of the company's regulatory standing.

TransData Nexus Research · FDA, WHO, EMA regulatory databasesMar 2026

Frequently Asked Questions — Vins Bioproducts Limited

How many pharmaceutical products does Vins Bioproducts Limited export from India?

Vins Bioproducts Limited exports 3 pharmaceutical products across 1 therapeutic categories. The top exports are Antitoxin ($9.0M), Serum ($6.0M), Immunoglobulin ($700.0K). Total export value is $15.7M.

What is Vins Bioproducts Limited's total pharmaceutical export value?

Vins Bioproducts Limited's total pharmaceutical export value is $15.7M, based on 383 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Vins Bioproducts Limited the #1 Indian exporter?

Vins Bioproducts Limited is the #1 Indian exporter in 1 products: Antitoxin (64.7% market share).

What therapeutic categories does Vins Bioproducts Limited cover?

Vins Bioproducts Limited exports across 1 therapeutic categories. The largest are Other (100.0%, 3 products).

Get Full Vins Bioproducts Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.